COVID-19 resources / Clinical Research Insights and News

The Cohortias Blog

Stay informed

COVID-19 resources

Cohortias is bringing clinical research to Latin America, now proud to participate in COVID-19 clinical trials.

Our archive includes insights from our experts as they discuss lessons learned over the past three months in managing COVID-19’s impact on trials in Latin America and around the world.

Our blog posts provide insights into what companies should be doing now to prepare for the upcoming ‘new normal’.

clinical-trials-Latin-america

US approves first new Alzheimer’s drug in almost two decades.

U.S. regulators on Monday approved Biogen Inc’s aducanumab as the first treatment to attack a likely cause of Alzheimer’s disease despite controversy over whether the clinical evidence proves the drug works.

covid-19-vaccine-China

COVID-19 – 21 vaccines enter clinical trials in China.

Four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for

clinical-trials

Phase II of Mir-19 anti-COVID drug clinical trial begins.

Head of Russia’s Federal Medical Biological Agency Veronika Skvortsova said that Mir-19 was based on micro-RNA that blocks certain parts of the RNA virus.

clinical trials

Clinical Trial – Medical Estudy for Alzheimer’s treatment.

Roughly more than 50 million people around the world are living with Alzheimer’s and experts hope a new clinical trial can change that.

COVID-19 Research - Free Consultation

The clinical development journey is fraught with pitfalls and roadblocks; COVID-19 has almost overnight added to the complexity. Innovations, technologies and reinvented processes can help. Our experienced team of experts shares experiences, lessons learned and tips to help you mitigate risk in the current environment while implementing some of the industry’s latest innovations.

covid clinical trials

The presence of clinical research in Latin America has been growing steadily for the last decade, mainly because of cost effectiveness, excellent patient recruitment and the emergence of FDA approved regulatory agencies.